CNIO752A12301 (The Preserve Study) | Clinical Research Studies Listing

Recruiting

99 years or below

All

Phase N/A

7 participants needed

1 Location

Brief description of study

This is a phase III, double-blind, placebo-controlled study to evaluate the efficacy and safety or NI0752 in participants with Progressive Supranuclear Palsy (PSP). Participants will receive either 50mg of NI0752 or placebo every 12 weeks for 72 weeks via intrathecal injection during the double-blind period followed by an OLE period.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: 99 years or below
Gender: All

TBD

Updated on 16 Jun 2026. Study ID: 26-5926

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

View email

Phone

View phone

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Please provide your preferred way of contact

Other language

By Submitting your information, you agree that your details may be shared with the selected study site and handled in accordance with this Website's Privacy Policy (see link in footer). You may be contacted by email, text message, or phone regarding this study and other research opportunities that may be of interested to you. You can unsubscribe from these communications at any time. Message and data rates may apply.

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center